Learn more

SYNAFFIX BV

Overview
  • Total Patents
    92
  • GoodIP Patent Rank
    18,139
  • Filing trend
    ⇩ 73.0%
About

SYNAFFIX BV has a total of 92 patent applications. It decreased the IP activity by 73.0%. Its first patent ever was published in 2011. It filed its patents most often in EPO (European Patent Office), United States and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets biotechnology, pharmaceuticals and organic fine chemistry are PERIMMUNE HOLDINGS INC, REDWOOD BIOSCIENCE INC and APPLIED NANOSYSTEMS BV.

Patent filings per year

Chart showing SYNAFFIX BVs patent filings per year from 1900 to 2020

Top inventors

# Name Total Patents
#1 Van Delft Floris Louis 85
#2 Wijdeven Maria Antonia 64
#3 Van Geel Remon 49
#4 Van Berkel Sander Sebastiaan 42
#5 Verkade Jorge Merijn Mathieu 37
#6 Heesbeen Ryan 25
#7 Van De Sande Petrus Josephus Jacobus Maria 21
#8 Hurkmans Inge Catharina Josephina 11
#9 Dommerholt Frederik Jan 10
#10 Rutjes Floris Petrus Johannes Theodorus 10

Latest patents

Publication Filing date Title
WO2020245229A1 Acetal-based cleavable linkers
JP2020090526A Modified antibodies, antibody conjugates and methods for preparing them
WO2020094670A1 Antibody-conjugates for targeting of tumours expressing trop-2
NL2023572B1 Synthesis of 6-azido-6-deoxy-2-N-acetyl-hexosamine-nucleoside diphosphate
WO2019110725A1 Enediyne conjugates
WO2017137459A1 Enzymes for trimming of glycoproteins
US2019038765A1 Sulfamide linkers for use in bioconjugates
US2019262468A1 Antibody-conjugates with improved therapeutic index for targeting cd30 tumours and method for improving therapeutic index of antibody-conjugates
US2019262467A1 Bioconjugates containing sulfamide linkers for use in treatment
CN108883191A Antibody-conjugate with improved therapeutic index for targeting CD30 tumour and the method for improving antibody-conjugate therapeutic index
WO2017137457A1 Antibody-conjugates with improved therapeutic index for targeting her2 tumours and method for improving therapeutic index of antibody-conjugates
JP2017197512A Novel antibody-conjugates with improved therapeutic index for targeting cd30 tumors and methods for improving therapeutic index of antibody-conjugates
JP2017200902A Novel antibody-conjugate with improved therapeutic index for targeting HER2 tumor and method for improving therapeutic index of antibody-conjugate
US2017130256A1 Process for the modification of a glycoprotein using a glycosyltransferase that is or is derived from A β(1,4)-N-acetylgalactosaminyltransferase
EP3598983A1 Sulfamide linker, conjugates thereof, and methods of preparation
WO2016022027A1 Process for the modification of a glycoprotein using a βeta-(1,4)-n-acetylgalactosaminyltransferase or a mutant thereof
US2017008858A1 Process for the cycloaddition of a halogenated 1,3-dipole compound with a (hetero)cycloalkyne
EP3097200A1 Process for the attachment of a galnac moiety comprising a (hetero)aryl group to a glcnac moiety, and product obtained thereby
EP3097079A1 Process for the cycloaddition of a hetero(aryl) 1,3-dipole compound with a (hetero)cycloalkyne
CN105814213A Modified glycoprotein, protein-conjugate and process for the preparation thereof